Last updated: July 24, 2026
Actelion v. Mylan (1:23-cv-00088): Litigation Summary, Claims at Issue, and Competitive Implications for Actelion’s Patent Estate
Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., case number 1:23-cv-00088, is a U.S. Hatch-Waxman-style patent dispute in which Actelion asserts infringement by Mylan tied to Actelion’s branded product(s) and their associated U.S. patent portfolio. The litigation’s business impact is determined by (1) the specific Orange Book-listed patents asserted, (2) the remaining term and any terminal disclaimers, (3) whether the case targets ANDA exclusivity carve-outs (180-day exclusivity, section viii carve-outs, or exclusivity forfeiture), and (4) whether Mylan’s proposed generic is entered via Paragraph IV certifications that trigger trial timing and potential settlement windows.
Actionable framing: the case affects Mylan’s ability to launch at risk and determines whether Actelion retains leverage for a settlement, a consent-to-entry framework, or injunction-based delay.
What are the asserted patents in Actelion v. Mylan 1:23-cv-00088?
Featured-snippet answer: The case record determines which Orange Book patents Actelion asserted and whether claims are directed to formulation, method of use, or manufacturing.
Why the asserted patent identity matters commercially
- Patent type drives design-around risk:
- Formulation/device-delivery patents are harder to work around without reformulating.
- Method-of-use patents can be sidestepped by labeling/carve-outs, if the generic sponsor can structure its proposed use and FDA labeling accordingly.
- Manufacturing method patents can be avoided through different process controls, if defensible claim scope permits.
Key litigation artifact to map
- The “patents-in-suit” list in the complaint and the infringement contentions define:
- statutory bases (35 U.S.C. § 271(a), (b), (c)),
- claim numbers,
- theory (direct infringement vs. induced/contributory),
- and the anticipated launch timeframe based on ANDA status.
When did Actelion sue Mylan in 1:23-cv-00088, and what is the procedural posture?
Featured-snippet answer: The case is filed in the U.S. District Court under 1:23-cv-00088 and proceeds on a schedule set by the Hatch-Waxman framework: early technical claim construction and expedited trial or stay dynamics if settlement occurs.
Timeline mapping that determines launch risk
- Filing date establishes the initial stay posture for the ANDA.
- Scheduling order milestones determine:
- claim construction timing,
- infringement and invalidity evidence deadlines,
- expert submission deadlines,
- and settlement leverage at each inflection point.
Business implication
- If the case remains in early phases, settlement probability remains higher.
- If claim construction is complete and dispositive motions are resolved, trial settlement dynamics shift toward cash-for-delay or stipulated entry.
What patents protect Actelion’s drug(s) against Mylan’s ANDA strategy?
Featured-snippet answer: Actelion’s asserted estate in this case is tied to its Orange Book-listed patents for the relevant branded product.
Patent estate segmentation that typically appears in these disputes
- Drug substance and polymorph patents
- Solid-state, salt, or particle engineering patents
- Formulation patents (excipients, coatings, dissolution profiles)
- Controlled-release or dosage form patents
- Methods of use tied to therapeutic regimens or clinical biomarkers
Litigation relevance
- The asserted claims will typically align with one of these segments. That alignment predicts:
- whether Mylan can carve out labeling to avoid method claims,
- whether Mylan can adjust dissolution/spec targets to reduce formulation infringement,
- and whether process differences can avoid manufacturing-method claims.
Does Actelion v. Mylan involve Paragraph IV ANDA certifications?
Featured-snippet answer: In Hatch-Waxman patent infringement cases with this captioning, the suit generally follows a Paragraph IV challenge to Orange Book-listed patents tied to Mylan’s ANDA.
What that implies for exclusivity and timing
- Paragraph IV certifications drive:
- automatic stay timing (or its expiration),
- potential 180-day exclusivity effects depending on first-filer status,
- and risk of forfeiture if settlement, later-filed amendments, or other statutory events occur.
Settlement leverage
- Paragraph IV cases commonly resolve through:
- stipulated non-infringement findings,
- agreed design-around specs,
- or entry dates tied to patent expiry.
How strong is Actelion’s patent position in this case based on litigation structure?
Featured-snippet answer: Strength is inferred from the claims selected, the court’s early rulings (if any), and whether invalidity arguments include common Art 102/103 patterns like obviousness, anticipation, or written description issues.
What to look for in the record
- Claim construction outcomes: narrow constructions reduce invalidity/infringement leverage for the challenger.
- Validity defenses advanced:
- anticipation (single reference),
- obviousness (multiple references),
- indefiniteness,
- § 112 enablement or written description.
- Evidence alignment:
- whether Actelion has experimental data supporting claimed parameters,
- whether prior art references map cleanly to each claim element.
Commercial inference
- Strong claim construction early tends to increase settlement odds and reduces at-risk launch probability.
What generic entry risks exist for Mylan if Actelion’s asserted patents expire soon?
Featured-snippet answer: If remaining patent term is short, Mylan’s risk shifts from “injunction” to “design-around and launch timing,” and settlement becomes more likely.
Key risk drivers
- Remaining term: earlier expiry reduces deterrence.
- Secondary patents: even if the primary patent expires, later patents can extend delay.
- Terminal disclaimers can affect whether expiration is fixed or extended across related families.
- Stays pending appeal: settlement vs. appeal determines whether Mylan benefits from trial-stage rulings.
Is biosimilar risk relevant in Actelion v. Mylan 1:23-cv-00088?
Featured-snippet answer: Biosimilar frameworks apply to biologics; this case caption indicates a Hatch-Waxman pathway for a small-molecule or drug product. Biosimilar risk is therefore not the central framework for exclusivity and infringement analysis in this docket.
What FDA regulatory status controls entry timing in 1:23-cv-00088?
Featured-snippet answer: FDA entry timing hinges on the relevant ANDA approval status (tentative approval vs. final approval), the Orange Book listing, and whether Mylan’s certification led to a statutory stay.
Regulatory mechanics that affect litigation leverage
- If an ANDA is tentatively approved, the legal stay can prevent effective approval.
- If a stay expires by time or settlement, FDA can proceed to approval and launch.
How does Actelion’s lawsuit affect Mylan’s commercialization timeline and market share?
Featured-snippet answer: The case can delay Mylan’s launch and keep Actelion’s branded revenue protected until resolution or expiry of the asserted patents.
Market impact model used by commercial teams
- Launch delay duration translates into:
- lost generic switching,
- continued payer contracts with branded incumbency,
- and potential volume protection on high-cost formularies.
Settlement structure common in these dockets
- Entry date settlement.
- Agreement on non-infringement for certain claim sets with stipulated design-around.
- Payment-for-delay is a risk for litigation; many resolutions instead use stipulated licensing-like entry terms.
What settlement outcomes are typical in Actelion v. Mylan-style Hatch-Waxman disputes?
Featured-snippet answer: Most resolutions fall into one of three patterns: entry-date agreements, covenants not to sue, or stipulated infringement/validity for limited claim sets.
Decision tree for business planning
- Settlement with agreed entry date: plan manufacturing and market launch to that date.
- Partial settlement: plan for limited risk areas, especially if only some patents are resolved.
- No settlement: plan for injunction risk until trial and appellate posture is resolved.
Key litigation checkpoints that change the risk profile in 1:23-cv-00088
Featured-snippet answer: Risk changes after claim construction, dispositive motions, and settlement events.
Checkpoint list
- Claim construction rulings affecting claim breadth.
- Summary judgment motions on invalidity or infringement.
- Trial date set or vacated due to settlement.
- Any consent judgments or stipulations that define the boundaries for entry.
Actelion vs. Mylan: How does the patent estate structure drive outcomes?
Featured-snippet answer: Outcomes depend on whether Actelion’s claims are central and non-design-around, or whether they can be avoided with labeling carve-outs, formulation changes, or alternate manufacturing.
Comparison of patent estate archetypes
- If Actelion’s asserted claims are composition/formulation:
- harder to work around.
- settlement odds increase.
- If asserted claims are method of use:
- labeling changes can reduce infringement risk.
- carve-outs can preserve a launch path.
Key Takeaways
- Actelion v. Mylan (1:23-cv-00088) is a patent infringement dispute tied to Orange Book-listed patents and Mylan’s ANDA regulatory pathway.
- The litigation’s business impact is governed by (1) the specific patents-in-suit and claim scope, (2) remaining patent term and terminal disclaimers, (3) whether Paragraph IV stay and exclusivity issues shape timing, and (4) whether the case resolves through entry-date settlement or proceeds through trial.
- Commercial teams should map risk to patent type (formulation vs. method-of-use vs. manufacturing) because it determines the feasibility of design-around and the probability of a settlement.
FAQs
1) What does “1:23-cv-00088” mean for Hatch-Waxman timing?
It identifies the federal docket; in Hatch-Waxman, it corresponds to expedited patent litigation tied to ANDA certification and Orange Book listings.
2) Do Actelion cases usually turn on claim construction?
Often they do; claim construction frequently drives infringement and invalidity leverage in scheduled decisions and settlement negotiations.
3) Can Mylan avoid liability by changing FDA labeling in this type of dispute?
If the asserted claims are method-of-use oriented, labeling carve-outs can be a key design-around tool.
4) How does settlement typically affect launch dates?
Settlements usually translate into an agreed effective date for FDA approval and/or product launch, or stipulations that narrow the remaining risk.
5) What litigation events most affect investment or licensing decisions?
Claim construction, summary judgment rulings, trial scheduling, and any consent or stipulated judgments that define the enforceable boundaries for generic entry.
References (APA)
- U.S. District Court docket: Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., 1:23-cv-00088.
